NEW YORK, December 30, 2025, 13:35 ET — Regular session
Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%.
The pullback came as U.S. stocks steadied in holiday-thin trading ahead of minutes from the Federal Reserve’s December policy meeting, after the central bank delivered a 25-basis-point cut this month. Mark Hackett, chief market strategist at Nationwide, described recent positioning as “a healthy rebalancing of allocations.” Reuters
Biotechnology shares were among the laggards, with the NYSE Arca Biotechnology Index down about 1.1% earlier in the session, Nasdaq.com data showed. That backdrop can amplify moves in smaller names as year-end liquidity dries up.
ADMA last updated investors on Nov. 5, when it reported third-quarter revenue of $134.2 million, up 12% from a year earlier, and GAAP net income of $36.4 million. The company said the FDA’s lot release of its first “yield-enhanced” batches — a manufacturing change designed to get more product from each volume of plasma — should support gross margin expansion starting in the fourth quarter, and it raised its full-year 2025 revenue outlook to $510 million or more. It also lifted its 2026 revenue forecast to $630 million or more and projected 2026 adjusted EBITDA — a common proxy for operating profit that excludes items such as interest, taxes and depreciation — of more than $355 million. GlobeNewswire
A quarterly filing described ADMA’s core business as plasma-derived immune globulin, an antibody-rich therapy made from human plasma. It sells ASCENIV and BIVIGAM for patients with primary immunodeficiency, and Nabi-HB for certain hepatitis B exposures.
A Form 4 filing showed President and CEO Adam Grossman exercised options for 15,000 shares and sold 21,000 shares at $19.79 on Dec. 15. The filing said the trades were made under a Rule 10b5-1 plan, a pre-arranged program that sets trading instructions in advance.
Plasma-product peers were mixed: Grifols shares were up about 0.6% on Tuesday, while Takeda’s U.S.-listed shares slipped about 0.9%. ADMA’s sharper move left it trading more like a small-cap biotech than the diversified plasma majors.
For ADMA bulls, the near-term question is execution: whether higher output translates into sustained margin gains as the yield-enhanced process ramps. Any shift in plasma availability or payer coverage can flow quickly into quarterly numbers for a company of its size.
For bears, the concern is that quiet tape-plus-thin liquidity can turn routine sector weakness into an outsized drawdown, even without a company-specific headline. That dynamic tends to fade once trading volume normalizes in January.
The next scheduled checkpoint is the company’s fourth-quarter report. ADMA has not confirmed a publication date, but MarketBeat estimates an earnings release on March 2, 2026, based on prior reporting patterns.
Until that update, traders are likely to keep treating ADMA as a high-beta read on biotech sentiment and rate expectations — factors that can overpower company narratives on slower news days. Swings in the biotech ETFs often set the tone first.
